Venrock

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Graphite Bio is a clinical-stage gene editing company focused on targeted DNA integration to treat serious diseases. Its platform aims to precisely insert, repair, or replace genetic sequences by integrating therapeutic cargoes at predefined genomic locations, enabling correction of mutations or replacement of disease-causing genes while preserving normal regulatory control. Based in South San Francisco, the company pursues high-efficiency precision gene editing to address underlying causes of disease.

Artiva Biotherapeutics, Inc. is a San Diego-based biotechnology company focused on developing and manufacturing cellular immunotherapies for cancer treatment. Founded in 2019, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating both hematologic cancers and solid tumors. The company's product pipeline includes therapies that target CD20 and CD19 in B-cell lymphomas, as well as HER2 in various solid tumors. Artiva is committed to harnessing the therapeutic potential of NK cells while addressing challenges in their scalability and manufacturing. Its mission centers on delivering effective and safe cell therapies that are readily accessible to cancer patients in need.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Federation Bio Inc., established in 2018 and headquartered in South San Francisco, California, specializes in the development of microbial therapeutics targeting diseases where the human microbiome holds curative potential. The company's platforms focus on secondary hyperoxaluria and explore treatments for metabolic disorders, immune diseases, and cancer. Federation Bio's approach involves leveraging naturally occurring or engineered bacteria alongside a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines across hematology, oncology, cardiovascular, and immunology. Its portfolio includes Opdivo for cancer immunotherapy; Eliquis for stroke prevention and venous thromboembolism; Orencia for rheumatoid arthritis; Sprycel, Yervoy, Empliciti, Baraclude; Reyataz and Sustiva for HIV; and Daklinza, Sunvepra, Beclabuvir for viral infections. The company sells products through wholesalers, retail pharmacies, hospitals, government entities, and medical professionals worldwide, and pursues collaboration and licensing arrangements with Pfizer, Otsuka, Ono, Nektar, AstraZeneca, Insitro, Schrödinger, and others. It also engages in partnerships for discovery and development with multiple biotech firms and academia. Founded in 1887 and headquartered in New York, the firm has a strong presence in immuno-oncology and focuses on innovative therapies and global reach.

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its products include Chromium platforms for single-cell gene expression analysis, immune profiling, epigenetics study, and spatial gene expression measurement. Serving academic, government, biopharmaceutical, and other institutions globally.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its products include Chromium platforms for single-cell gene expression analysis, immune profiling, epigenetics study, and spatial gene expression measurement. Serving academic, government, biopharmaceutical, and other institutions globally.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing innovative treatments for cardiopulmonary diseases. Headquartered in Warren, New Jersey, the company focuses on its proprietary INOpulse platform, which delivers pulsatile nitric oxide, targeting various forms of pulmonary hypertension. Bellerophon is advancing multiple product candidates through clinical trials, including treatments for pulmonary hypertension associated with interstitial lung disease and chronic obstructive pulmonary disease, as well as other conditions such as sarcoidosis and chronic thromboembolic pulmonary hypertension. Additionally, Bellerophon is exploring a bioabsorbable cardiac matrix device aimed at preventing cardiac remodeling after myocardial infarction, currently undergoing a feasibility clinical trial in the European Union. Founded in 2009 and previously known as Ikaria Development LLC, Bellerophon Therapeutics aims to address significant unmet medical needs in the cardiopulmonary space.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company based in Charlotte, North Carolina, specializing in the acquisition, development, and commercialization of treatments for various human diseases. The company is focused on developing a therapeutic agent for symptomatic neurogenic orthostatic hypotension and related conditions. Additionally, Chelsea Therapeutics is engaged in developing prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. The company's research efforts center on two main projects: droxidopa for symptomatic neurogenic orthostatic hypotension and a portfolio of non-metabolized antifolate compounds aimed at treating rheumatoid arthritis.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

XenoPort, Inc. is a biopharmaceutical company based in Santa Clara, California, that specializes in the development and commercialization of a portfolio of product candidates aimed at treating neurological and other disorders. The company markets HORIZANT (gabapentin enacarbil) extended-release tablets in the United States for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults. Its pipeline includes XP23829, a fumaric acid ester compound in Phase III trials for psoriasis and relapsing forms of multiple sclerosis, and arbaclofen placarbil, currently in Phase II trials for spasticity in multiple sclerosis. Additionally, XP21279, aimed at treating advanced idiopathic Parkinson's disease, has completed Phase II trials. XenoPort has secured licensing and collaboration agreements with various pharmaceutical companies to further develop its products. Founded in 1999, XenoPort became a subsidiary of Arbor Pharmaceuticals, LLC in July 2016.

Biospect, Inc. is a South San Francisco-based life sciences technology company focused on developing minimally invasive solutions for identifying and analyzing protein biomarker patterns. These patterns are crucial for differentiating various biological states, which aids in diagnosing and managing diseases, as well as facilitating drug development. The company integrates proprietary technologies in separations, detection, and informatics to create a comprehensive system designed for medical research applications. By advancing the capabilities of biomarker analysis, Biospect aims to enhance the effectiveness of disease management and therapeutic innovation.

Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.

Infinity Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Its lead product, eganelisib, is an oral immuno-oncology agent designed to reprogram macrophages and address immune suppression in cancer. Infinity is conducting multiple clinical studies, including the global MARIO-275 trial, which investigates eganelisib in combination with Opdivo® for patients with urothelial cancer. The company is also exploring eganelisib in various combinations for front-line treatment in advanced cancers, including triple-negative breast cancer and renal cell carcinoma, evaluating it alongside other therapeutics such as Tecentriq® and Abraxane®. Additionally, Infinity is collaborating with Arcus Biosciences to assess a novel regimen combining eganelisib with etrumadenant and Doxil® in advanced triple-negative breast cancer patients. The company is committed to developing treatments for various hematologic malignancies and solid tumors, leveraging its strategic partnerships to advance its oncology programs.

XenoPort, Inc. is a biopharmaceutical company based in Santa Clara, California, that specializes in the development and commercialization of a portfolio of product candidates aimed at treating neurological and other disorders. The company markets HORIZANT (gabapentin enacarbil) extended-release tablets in the United States for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults. Its pipeline includes XP23829, a fumaric acid ester compound in Phase III trials for psoriasis and relapsing forms of multiple sclerosis, and arbaclofen placarbil, currently in Phase II trials for spasticity in multiple sclerosis. Additionally, XP21279, aimed at treating advanced idiopathic Parkinson's disease, has completed Phase II trials. XenoPort has secured licensing and collaboration agreements with various pharmaceutical companies to further develop its products. Founded in 1999, XenoPort became a subsidiary of Arbor Pharmaceuticals, LLC in July 2016.

XenoPort, Inc. is a biopharmaceutical company based in Santa Clara, California, that specializes in the development and commercialization of a portfolio of product candidates aimed at treating neurological and other disorders. The company markets HORIZANT (gabapentin enacarbil) extended-release tablets in the United States for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults. Its pipeline includes XP23829, a fumaric acid ester compound in Phase III trials for psoriasis and relapsing forms of multiple sclerosis, and arbaclofen placarbil, currently in Phase II trials for spasticity in multiple sclerosis. Additionally, XP21279, aimed at treating advanced idiopathic Parkinson's disease, has completed Phase II trials. XenoPort has secured licensing and collaboration agreements with various pharmaceutical companies to further develop its products. Founded in 1999, XenoPort became a subsidiary of Arbor Pharmaceuticals, LLC in July 2016.

Illumina develops and sells advanced genomic sequencing tools and workflows used in research, clinical laboratories, and industry. It provides high-throughput sequencing instruments, consumables, and services that enable whole genome sequencing in humans and other organisms, as well as lower-throughput applications for targeted analysis such as viral and cancer screening. The company's technology supports analysis of DNA, RNA, and protein to study genetic variation and function, facilitating disease research, drug development, and molecular diagnostics in clinical settings. It emphasizes scalable, flexible solutions and strong customer service, aiming to advance personalized medicine through rapid delivery of innovative sequencing and analysis capabilities. In addition to sequencing, Illumina offers microarrays that enable cost-effective screening for consumer and agricultural applications, contributing to a broad portfolio across life sciences.

Symyx Technologies develops and applies research technologies and software for industries such as chemicals, energy, life sciences, and consumer products. The company offers research services for collaborative partners and provides tools like high-throughput reactors, screening systems, and robots, integrated with software to aid in research and development processes. Symyx licenses automation, data mining applications, and ELN software to enhance experiment design, laboratory automation, data capture, analysis, visualization, and communication in high-throughput and traditional research settings.

Caliper Life Sciences, Inc. is a provider of products and services tailored for pharmaceutical and biotechnology companies, as well as government and nonprofit research institutions. The company specializes in integrated systems that encompass instruments, software, reagents, and laboratory automation tools, aimed at enhancing the drug discovery and development process. Its offerings include advanced technologies for molecular imaging, microfluidics, and liquid handling, which address critical challenges in research. Notable products include IVIS Imaging Systems for optical molecular imaging, LabChip systems for drug discovery that enhance data accuracy, and automated liquid handling instruments such as the Caliper Sciclone. Additionally, Caliper provides contract research services, transgenic animal services, and comprehensive support for drug discovery. Founded in 1995 and headquartered in Hopkinton, Massachusetts, Caliper Life Sciences sells its products through a dedicated sales force and a network of distributors, helping researchers streamline their workflows and improve the efficiency of preclinical studies.

Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.

Signal Pharmaceuticals is a California-based biopharmaceutical company founded by David Anderson, Alan Lewis, Mark Carmen, and Jackie Johnson. The company focuses on the research and development of small-molecule drugs aimed at regulating gene expression associated with various diseases. In 2009, Signal Pharmaceuticals was acquired by Celgene, expanding its capabilities and resources in the biopharmaceutical sector.

Vical develops biopharmaceuticals focused on preventing and treating chronic or life-threatening infectious diseases and dermatologic conditions. Rooted in DNA vaccine and non-viral gene therapy technology, the company has built a portfolio of independent and partnered development programs. The first animal health products are on the market, while human products are advancing. In addition to infectious disease therapies, the company pursues treatments for skin diseases such as hyperhidrosis, Cutaneous T-cell lymphoma, and psoriasis. Its pipeline includes Sofpironium Bromide and other candidates such as BBI-3000 and BBI-6000.

Sugen is a biotechnology company that specializes in target-driven drug discovery and development for novel development-stage cancer therapies. It develops new therapeutic approaches to various diseases through its development of small molecule inhibitors that regulate particular signaling pathways. Sugen owns three anti-cancer drugs in clinical development, including novel cytostatic agents and angiogenesis inhibitors. In addition to its current focus in oncology, Sugen is applying its technology platform to identify and validate novel targets for a range of potential clinical applications.

PerSeptive Biosystems develops instrumentation systems and consumable products for the purification, analysis, and synthesis of biomolecules. It develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers of PerSeptive Biosystems use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Founded in 1989, PerSeptive Biosystems is based in Framingham, Massachusetts. Currently, it operates as a subsidiary of Life Technologies Corporation.

Gilead Sciences is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines for life-threatening diseases. Its primary focus areas include HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions.

IDEC Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurodegenerative, hematologic, and autoimmune diseases. Founded in 1986 by physician and immunologist Ivor Royston, bioentrepreneur Howard Birndorf, and cancer researchers Ron Levy and Richard Miller, the company initially aimed to develop and commercialize monoclonal antibodies. IDEC Pharmaceuticals has made significant contributions to the treatment of non-Hodgkin's lymphoma, employing patient-specific approaches to enhance therapeutic effectiveness. In 2003, IDEC merged with Biogen, further expanding its capabilities in the biopharmaceutical sector.

Athena Neurosciences is focused on the research and development of therapeutic products for neurological diseases. Athena Neurosciences was founded by Larry Bock and Lawrence Fritz.

Sunovion Pharmaceuticals Inc. is a biopharmaceutical company based in Marlborough, Massachusetts, dedicated to the development and commercialization of innovative therapeutic products for patients with central nervous system disorders, respiratory conditions, and other serious illnesses. The company offers a range of medications, including those for insomnia, schizophrenia, bipolar depression, epilepsy, asthma, and chronic obstructive pulmonary disease. Notable products include LUNESTA for sleep disorders, LATUDA for schizophrenia, and various inhalation solutions for respiratory issues. Sunovion's pipeline includes promising treatments such as Apomorphine Sublingual Film for Parkinson's disease and Lonhala Magnair for COPD. Founded in 1984 and formerly known as Sepracor, Sunovion operates as a subsidiary of Sumitomo Dainippon Pharma America, Inc. and is committed to enhancing patient care through ongoing research and development.

IDEXX Laboratories, Inc. specializes in developing, manufacturing, and distributing diagnostic products and services for the companion animal, livestock, poultry, dairy, and water testing markets globally. The company operates through several segments, including Companion Animal Group, Water Quality Products, Livestock, Poultry, and Dairy, among others. IDEXX offers a wide range of point-of-care veterinary diagnostic tools, instruments, and rapid assay test kits, as well as reference laboratory services and practice management software for veterinarians. Additionally, the company provides diagnostic tests for livestock and poultry health management and water quality testing to ensure safety. IDEXX's products enhance veterinary care capabilities, improve operational efficiency, and support the economic success of veterinary practices. With over 4,900 employees, IDEXX Laboratories serves customers in more than 100 countries and generates a significant portion of its revenue from international markets. The company is headquartered in Westbrook, Maine.

Liposome Company manufactures commercialized drug delivery systems based on liposomes.

Centocor is an integrated biopharmaceutical company developing monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.